Venous thromboembolism events among RA patients.
C-Reactive Protein
Rheumatoid arthritis
autoimmune diseases
deep vein thrombosis
thrombosis
venous thromboembolism
Journal
Mediterranean journal of rheumatology
ISSN: 2529-198X
Titre abrégé: Mediterr J Rheumatol
Pays: Greece
ID NLM: 101730166
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
17
12
2018
revised:
29
12
2018
accepted:
07
01
2019
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
Rheumatoid arthritis (RA) is associated with an increased risk for venous thromboembolism. However, so far, relatively few and small size-based studies have been conducted. We aimed to investigate the link between RA and venous thromboembolism utilizing a large sample of subjects originating from a large data base. The study was performed utilizing the medical database of Clalit Health Services, the largest healthcare provider in Israel. We enrolled all patients with RA and age- and gender-matched controls. Chi-square and t-tests were used for univariate analysis and a logistic regression model was used for a multivariate analysis. RA patients were compared to controls regarding the proportion of venous thromboembolic events (defined as deep vein thrombosis, pulmonary embolism or both). Multivariate logistic regression was employed to assess factors associated with thromboembolic events. The study included 11,782 patients with RA and 57,973 age- and gender-matched controls. RA patients had a higher rate of venous thromboembolism events compared with controls (6.92% vs. 3.18%, respectively, p<0.001). RA and mean C-reactive protein levels were found to be independently associated with the proportion of thromboembolic events (OR 2.27 for RA and 1.07 for each 1 mg/dL increment of mean C-reactive protein, respectively). RA and C-reactive protein levels are independently associated with venous thromboembolic events. Physicians should be aware of such findings and have a lower threshold for suspecting detecting such events in patients with RA, mainly those with mean high levels of C-reactive protein.
Sections du résumé
BACKGROUND
BACKGROUND
Rheumatoid arthritis (RA) is associated with an increased risk for venous thromboembolism. However, so far, relatively few and small size-based studies have been conducted. We aimed to investigate the link between RA and venous thromboembolism utilizing a large sample of subjects originating from a large data base.
MATERIALS AND METHODS
METHODS
The study was performed utilizing the medical database of Clalit Health Services, the largest healthcare provider in Israel. We enrolled all patients with RA and age- and gender-matched controls. Chi-square and t-tests were used for univariate analysis and a logistic regression model was used for a multivariate analysis. RA patients were compared to controls regarding the proportion of venous thromboembolic events (defined as deep vein thrombosis, pulmonary embolism or both). Multivariate logistic regression was employed to assess factors associated with thromboembolic events.
RESULTS
RESULTS
The study included 11,782 patients with RA and 57,973 age- and gender-matched controls. RA patients had a higher rate of venous thromboembolism events compared with controls (6.92% vs. 3.18%, respectively, p<0.001). RA and mean C-reactive protein levels were found to be independently associated with the proportion of thromboembolic events (OR 2.27 for RA and 1.07 for each 1 mg/dL increment of mean C-reactive protein, respectively).
CONCLUSION
CONCLUSIONS
RA and C-reactive protein levels are independently associated with venous thromboembolic events. Physicians should be aware of such findings and have a lower threshold for suspecting detecting such events in patients with RA, mainly those with mean high levels of C-reactive protein.
Identifiants
pubmed: 32185341
doi: 10.31138/mjr.30.1.38
pii: MJR-30-1-38
pmc: PMC7045915
doi:
Types de publication
Journal Article
Langues
eng
Pagination
38-43Informations de copyright
© 2019 The Mediterranean Journal of Rheumatology (MJR).
Références
Blood. 2013 Nov 14;122(20):3415-22
pubmed: 24092932
Clin Chem. 2015 Feb;61(2):349-59
pubmed: 25278501
Int J Clin Pract. 2018 Jan;72(1):
pubmed: 29231278
Clin Rheumatol. 2017 Apr;36(4):807-816
pubmed: 28127640
N Engl J Med. 2007 Dec 13;357(24):2482-94
pubmed: 18077812
Am J Cardiovasc Dis. 2012;2(3):171-83
pubmed: 22937487
Ann Rheum Dis. 2014 Jun;73(6):954-7
pubmed: 24431395
J Thromb Thrombolysis. 2017 Oct;44(3):377-385
pubmed: 28730407
Ann Rheum Dis. 2009 Jul;68(7):1232-3
pubmed: 19525410
Clin Exp Rheumatol. 2012 Sep-Oct;30(5):720-8
pubmed: 22766304
Immunol Res. 2017 Apr;65(2):459-463
pubmed: 28093682
Am J Med. 2016 Sep;129(9):1000.e15-25
pubmed: 27012853
Neuroepidemiology. 2018;50(1-2):1-6
pubmed: 29208845
Arthritis Res Ther. 2013;15(6):R194
pubmed: 24245495
Ann Rheum Dis. 2013 Nov;72(11):1764-70
pubmed: 23852762
Arthritis Res Ther. 2015 Mar 04;17:41
pubmed: 25889630
Arthritis Rheum. 2012 Jan;64(1):53-61
pubmed: 21905005
Ann Rheum Dis. 2014 Oct;73(10):1774-80
pubmed: 23926057
BMC Med. 2011 Jan 10;9:1
pubmed: 21219637
Arthritis Rheum. 1976 Nov-Dec;19(6):1237-43
pubmed: 999734
Semin Thromb Hemost. 2015 Sep;41(6):556-62
pubmed: 26276936
Autoimmun Rev. 2016 Apr;15(4):393-6
pubmed: 26808075
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Cardiovasc Res. 2005 Oct 1;68(1):47-55
pubmed: 16023093
Arthritis Rheum. 2002 Sep;46(9):2268-79
pubmed: 12355473
Int J Cardiol. 2017 Aug 15;241:41-45
pubmed: 28285799
Semin Arthritis Rheum. 2012 Feb;41(4):535-44
pubmed: 22340996
J Rheumatol. 2016 Sep;43(9):1622-30
pubmed: 27307523